Form 4: SOPHiA GENETICS CEO Sells Shares for Tax Withholding

SOPHiA GENETICS SA CEO Jurgi Camblong sold a total of 4,750 ordinary shares to cover tax obligations related to vested restricted stock units, as disclosed in a Form 4 filing.

Summary

• Jurgi Camblong, CEO and Director of SOPHiA GENETICS SA, reported the sale of 2,800 ordinary shares on April 8, 2026, and 1,950 ordinary shares on April 9, 2026.
• These sales were conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units.
• The transactions were executed under a Rule 10b5-1 trading plan, indicating they were pre-arranged and not discretionary.
• The weighted average sale price for the April 8 transaction was $4.8404, with individual sales ranging from $4.78 to $4.94.
• The weighted average sale price for the April 9 transaction was $4.7404, with individual sales ranging from $4.665 to $4.85.
• Following these transactions, Camblong beneficially owns 3,724,200 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves insider selling, the clear explanation of tax withholding obligations and the use of a Rule 10b5-1 plan mitigate negative sentiment.

Positives

• The sales were executed under a Rule 10b5-1 trading plan, which is a standard and compliant method for executives to sell shares.
• The sales were specifically to cover tax withholding obligations, a common and expected event for executives upon vesting of equity awards.
• The CEO continues to hold a significant number of shares (3,724,200) after the transactions.

Negatives

• The CEO sold a portion of their holdings, which could be perceived negatively by the market, although the reason is for tax obligations.
• The weighted average sale prices indicate a slight decrease in value from April 8 to April 9.

Risks

• The filing does not explicitly mention any new risks or challenges.
• Potential market perception of insider selling, even if for tax purposes, could create downward pressure on the stock price.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports on past transactions.

Management Comments

• Sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for publicly traded companies, detailing changes in beneficial ownership by insiders. The use of Rule 10b5-1 plans is a common practice for executives to manage equity sales in a compliant manner, particularly for covering tax liabilities.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO, even for tax purposes, might be interpreted as a negative signal by some investors, potentially impacting short-term stock price sentiment. However, the pre-planned nature and tax-related reason should temper this impact.
• Employees: The transaction does not directly impact employees, but it relates to executive compensation structures.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• The company may receive written requests for detailed sales information from the issuer, security holders, or the SEC staff.
• Continued adherence to the Rule 10b5-1 trading plan for any future transactions.

Key Dates

Keywords

SOPHiA GENETICS SA, Form 4, Insider Trading, Stock Sale, CEO, Jurgi Camblong, Tax Withholding, Restricted Stock Units, Rule 10b5-1, Beneficial Ownership